Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery

Masashi Kondo, Toshihiko Yokoyama, Takayuki Fukui, Hiromu Yoshioka, Kohei Yokoi, Tetsuro Nagasaka, Kazuyoshi Imaizumi, Hiroaki Kume, Yoshinori Hasegawa, Kaoru Shimokata, Yoshitaka Sekido

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The epidermal growth factor receptor (EGFR) gene has recently been reported to be mutated in a subset of non-small cell lung cancers (NSCLC), with the mutations being correlated with the patients' drug sensitivity to gefitinib, an EGFR kinase inhibitor. In this study, we searched for EGFR mutations in patients with lung cancer using primary tumor specimens obtained at initial surgery and examined whether their recurrent tumors showed a response to gefitinib depending on the presence of the activating mutation. Among 12 lung cancers that were treated with gefitinib after recurrence, we found that all four tumors which showed a response to gefitinib had an activating mutation in EGFR, whereas none of the remaining eight tumors had a mutation. Southern blot analysis showed that two of the four responsive tumors had the EGFR gene amplification. We also examined another 73 NSCLC specimens (47 males and 26 females; 53 adenocarcinomas and 20 non-adenocarcinomas) which were not treated with gefitinib to determine whether NSCLCs with an EGFR mutation have different clinicopathological properties and/or unique genetic alterations of the other cancer-associated genes. We found that 13 (18%) of 73 tumors had a mutation of the EGFR gene, with the most being detected in female adenocarcinomas. Comparing the alterations in KRAS and P53 with the EGFR mutation, we found that 10 tumors with the KRAS mutation did not have an EGFR mutation, suggesting that each mutation occurs exclusively during the development of lung cancer. These results suggest that the mutation analysis of the EGFR gene using the specimens obtained at surgery might be useful in selecting the appropriate treatment(s) for recurrent lung cancer patients.

Original languageEnglish
Pages (from-to)385-391
Number of pages7
JournalLung Cancer
Volume50
Issue number3
DOIs
Publication statusPublished - 01-12-2005

Fingerprint

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Recurrence
Mutation
erbB-1 Genes
Lung Neoplasms
Neoplasms
gefitinib
Adenocarcinoma
Gene Amplification
Neoplasm Genes
Southern Blotting

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Kondo, Masashi ; Yokoyama, Toshihiko ; Fukui, Takayuki ; Yoshioka, Hiromu ; Yokoi, Kohei ; Nagasaka, Tetsuro ; Imaizumi, Kazuyoshi ; Kume, Hiroaki ; Hasegawa, Yoshinori ; Shimokata, Kaoru ; Sekido, Yoshitaka. / Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. In: Lung Cancer. 2005 ; Vol. 50, No. 3. pp. 385-391.
@article{397b918dffd043e6b3162df9aef90df0,
title = "Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery",
abstract = "The epidermal growth factor receptor (EGFR) gene has recently been reported to be mutated in a subset of non-small cell lung cancers (NSCLC), with the mutations being correlated with the patients' drug sensitivity to gefitinib, an EGFR kinase inhibitor. In this study, we searched for EGFR mutations in patients with lung cancer using primary tumor specimens obtained at initial surgery and examined whether their recurrent tumors showed a response to gefitinib depending on the presence of the activating mutation. Among 12 lung cancers that were treated with gefitinib after recurrence, we found that all four tumors which showed a response to gefitinib had an activating mutation in EGFR, whereas none of the remaining eight tumors had a mutation. Southern blot analysis showed that two of the four responsive tumors had the EGFR gene amplification. We also examined another 73 NSCLC specimens (47 males and 26 females; 53 adenocarcinomas and 20 non-adenocarcinomas) which were not treated with gefitinib to determine whether NSCLCs with an EGFR mutation have different clinicopathological properties and/or unique genetic alterations of the other cancer-associated genes. We found that 13 (18{\%}) of 73 tumors had a mutation of the EGFR gene, with the most being detected in female adenocarcinomas. Comparing the alterations in KRAS and P53 with the EGFR mutation, we found that 10 tumors with the KRAS mutation did not have an EGFR mutation, suggesting that each mutation occurs exclusively during the development of lung cancer. These results suggest that the mutation analysis of the EGFR gene using the specimens obtained at surgery might be useful in selecting the appropriate treatment(s) for recurrent lung cancer patients.",
author = "Masashi Kondo and Toshihiko Yokoyama and Takayuki Fukui and Hiromu Yoshioka and Kohei Yokoi and Tetsuro Nagasaka and Kazuyoshi Imaizumi and Hiroaki Kume and Yoshinori Hasegawa and Kaoru Shimokata and Yoshitaka Sekido",
year = "2005",
month = "12",
day = "1",
doi = "10.1016/j.lungcan.2005.06.008",
language = "English",
volume = "50",
pages = "385--391",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "3",

}

Kondo, M, Yokoyama, T, Fukui, T, Yoshioka, H, Yokoi, K, Nagasaka, T, Imaizumi, K, Kume, H, Hasegawa, Y, Shimokata, K & Sekido, Y 2005, 'Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery', Lung Cancer, vol. 50, no. 3, pp. 385-391. https://doi.org/10.1016/j.lungcan.2005.06.008

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery. / Kondo, Masashi; Yokoyama, Toshihiko; Fukui, Takayuki; Yoshioka, Hiromu; Yokoi, Kohei; Nagasaka, Tetsuro; Imaizumi, Kazuyoshi; Kume, Hiroaki; Hasegawa, Yoshinori; Shimokata, Kaoru; Sekido, Yoshitaka.

In: Lung Cancer, Vol. 50, No. 3, 01.12.2005, p. 385-391.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery

AU - Kondo, Masashi

AU - Yokoyama, Toshihiko

AU - Fukui, Takayuki

AU - Yoshioka, Hiromu

AU - Yokoi, Kohei

AU - Nagasaka, Tetsuro

AU - Imaizumi, Kazuyoshi

AU - Kume, Hiroaki

AU - Hasegawa, Yoshinori

AU - Shimokata, Kaoru

AU - Sekido, Yoshitaka

PY - 2005/12/1

Y1 - 2005/12/1

N2 - The epidermal growth factor receptor (EGFR) gene has recently been reported to be mutated in a subset of non-small cell lung cancers (NSCLC), with the mutations being correlated with the patients' drug sensitivity to gefitinib, an EGFR kinase inhibitor. In this study, we searched for EGFR mutations in patients with lung cancer using primary tumor specimens obtained at initial surgery and examined whether their recurrent tumors showed a response to gefitinib depending on the presence of the activating mutation. Among 12 lung cancers that were treated with gefitinib after recurrence, we found that all four tumors which showed a response to gefitinib had an activating mutation in EGFR, whereas none of the remaining eight tumors had a mutation. Southern blot analysis showed that two of the four responsive tumors had the EGFR gene amplification. We also examined another 73 NSCLC specimens (47 males and 26 females; 53 adenocarcinomas and 20 non-adenocarcinomas) which were not treated with gefitinib to determine whether NSCLCs with an EGFR mutation have different clinicopathological properties and/or unique genetic alterations of the other cancer-associated genes. We found that 13 (18%) of 73 tumors had a mutation of the EGFR gene, with the most being detected in female adenocarcinomas. Comparing the alterations in KRAS and P53 with the EGFR mutation, we found that 10 tumors with the KRAS mutation did not have an EGFR mutation, suggesting that each mutation occurs exclusively during the development of lung cancer. These results suggest that the mutation analysis of the EGFR gene using the specimens obtained at surgery might be useful in selecting the appropriate treatment(s) for recurrent lung cancer patients.

AB - The epidermal growth factor receptor (EGFR) gene has recently been reported to be mutated in a subset of non-small cell lung cancers (NSCLC), with the mutations being correlated with the patients' drug sensitivity to gefitinib, an EGFR kinase inhibitor. In this study, we searched for EGFR mutations in patients with lung cancer using primary tumor specimens obtained at initial surgery and examined whether their recurrent tumors showed a response to gefitinib depending on the presence of the activating mutation. Among 12 lung cancers that were treated with gefitinib after recurrence, we found that all four tumors which showed a response to gefitinib had an activating mutation in EGFR, whereas none of the remaining eight tumors had a mutation. Southern blot analysis showed that two of the four responsive tumors had the EGFR gene amplification. We also examined another 73 NSCLC specimens (47 males and 26 females; 53 adenocarcinomas and 20 non-adenocarcinomas) which were not treated with gefitinib to determine whether NSCLCs with an EGFR mutation have different clinicopathological properties and/or unique genetic alterations of the other cancer-associated genes. We found that 13 (18%) of 73 tumors had a mutation of the EGFR gene, with the most being detected in female adenocarcinomas. Comparing the alterations in KRAS and P53 with the EGFR mutation, we found that 10 tumors with the KRAS mutation did not have an EGFR mutation, suggesting that each mutation occurs exclusively during the development of lung cancer. These results suggest that the mutation analysis of the EGFR gene using the specimens obtained at surgery might be useful in selecting the appropriate treatment(s) for recurrent lung cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=33644545057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644545057&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2005.06.008

DO - 10.1016/j.lungcan.2005.06.008

M3 - Article

VL - 50

SP - 385

EP - 391

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 3

ER -